Live from the NIH registry
Studies recruiting near Augusta right now
Top 25 of 188 recruiting studies, sorted by proximity — each links to its official registry page
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
Phase 2
Interventional 81 participants sought
Augusta University Medical Center — Augusta, Georgia (9.2 mi)
· Sponsor: National Cancer Institute (NCI)
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma
Phase 2
Interventional 40 participants sought
Ohio State University-Telemedicine — Augusta, Georgia (9.2 mi)
· Sponsor: Sameek Roychowdhury
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Non-Small Cell Lung Cancer (NSCLC)
Phase 3
Interventional 750 participants sought
Local Institution - 0412 — Augusta, Georgia (9.2 mi)
· Sponsor: Bristol-Myers Squibb
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Solid Tumors, Hematologic Malignancies
Phase 3
Interventional 3,500 participants sought
Augusta University ( Site 0077) — Augusta, Georgia (9.2 mi)
· Sponsor: Merck Sharp & Dohme LLC
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
B Acute Lymphoblastic Leukemia
Phase 2
Interventional 222 participants sought
Augusta University Medical Center — Augusta, Georgia (9.2 mi)
· Sponsor: National Cancer Institute (NCI)
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Large B-cell Lymphoma
Phase 2
Interventional 250 participants sought
Augusta University Georgia Cancer Center — Augusta, Georgia (9.2 mi)
· Sponsor: Allogene Therapeutics
Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema
Diabetic Retinopathy
Phase 2, Phase 3
Interventional 576 participants sought
Southeast Retina Center /ID# 274739 — Augusta, Georgia (9.2 mi)
· Sponsor: AbbVie
Improving Safety and Quality of Tracheal Intubation Practice in Pediatric ICUs
Failed or Difficult Intubation, Sequela, Intubation; Difficult
N/A
Observational 150,000 participants sought
Children's Hospital of Georgia — Augusta, Georgia (9.2 mi)
· Sponsor: Children's Hospital of Philadelphia
A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
Sickle Cell Disease
Phase 1
Interventional 24 participants sought
Augusta University — Augusta, Georgia (9.2 mi)
· Sponsor: Disc Medicine, Inc
Quality of End-of-Life Care for Children With Cancer
Childhood Hematopoietic and Lymphatic System Neoplasm, Childhood Malignant Solid Neoplasm
N/A
Observational 2,425 participants sought
Augusta University Medical Center — Augusta, Georgia (9.2 mi)
· Sponsor: Children's Oncology Group
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8
Phase 3
Interventional 474 participants sought
Augusta University Medical Center — Augusta, Georgia (9.2 mi)
· Sponsor: NRG Oncology
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
Cystic Fibrosis
N/A
Observational 400 participants sought
Augusta University — Augusta, Georgia (9.2 mi)
· Sponsor: Nicole Hamblett
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Malignant Solid Neoplasm
N/A
Observational 2,062 participants sought
Augusta Oncology Associates PC-D'Antignac — Augusta, Georgia (9.2 mi)
· Sponsor: SWOG Cancer Research Network
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Schizophrenia, Schizoaffective Disorder
Phase 4
Interventional 50 participants sought
Neurocrine Clinical Site — Augusta, Georgia (9.2 mi)
· Sponsor: Neurocrine Biosciences
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
Parkinson Disease
Phase 2
Interventional 150 participants sought
Augusta University Medical Center (Site #212) — Augusta, Georgia (9.2 mi)
· Sponsor: Appello Pharmaceuticals, Inc.
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
High Grade Osteosarcoma, Localized Osteosarcoma
Phase 2, Phase 3
Interventional 1,122 participants sought
Augusta University Medical Center — Augusta, Georgia (9.2 mi)
· Sponsor: National Cancer Institute (NCI)
Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration
Age-related Wet Macular Degeneration
Phase 1
Interventional 45 participants sought
CBCC Global Research Site:001 — Augusta, Georgia (9.2 mi)
· Sponsor: Caregen Co. Ltd.
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Ovarian Cancer, Fallopian Tube Cancer
Phase 3
Interventional 770 participants sought
Augusta University - Georgia Cancer Center ( Site 0066) — Augusta, Georgia (9.2 mi)
· Sponsor: Merck Sharp & Dohme LLC
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia
Phase 3
Interventional 303 participants sought
Augusta University Medical Center — Augusta, Georgia (9.2 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Acute Myeloid Leukaemia (AML)
Phase 2, Phase 3
Interventional 312 participants sought
Augusta University - Georgia Cancer Center — Augusta, Georgia (9.2 mi)
· Sponsor: Moleculin Biotech, Inc.
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
Cardiovascular Risk, Acute Myocardial Infarction (AMI)
Phase 3
Interventional 10,000 participants sought
Augusta University — Augusta, Georgia (9.2 mi)
· Sponsor: Novo Nordisk A/S
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
Geographic Atrophy, Macular Degeneration
N/A
Observational 500 participants sought
Southeast Retina Center, P.C. — Augusta, Georgia (9.2 mi)
· Sponsor: Astellas Pharma Global Development, Inc.
Sensor-based Congestion ALert for Events in Peritoneal Dialysis (SCALE-PD)
Kidney Disease, Peritoneal Dialysis (PD)
N/A
Observational 125 participants sought
Southeastern Clinical Research Institute — Augusta, Georgia (9.2 mi)
· Sponsor: Bodyport Inc.
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Phase 2
Interventional 335 participants sought
Augusta University Medical Center — Augusta, Georgia (9.2 mi)
· Sponsor: National Cancer Institute (NCI)
Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age
Hyperkalemia
Phase 2
Interventional 32 participants sought
Augusta University - Children's Hospital of Georgia — Augusta, Georgia (9.2 mi)
· Sponsor: Vifor Pharma, Inc.